Enabling Protein Degradation Drug Discovery

Jason Mundin MBA

Chief Executive Officer, Board Member

Jason has over 30 years’ experience in the pharmaceutical and biotechnology industries. He joined Ubiquigent in 2015 as Commercial Director, becoming Managing Director in 2018 and CEO in 2021.  Jason began his career as a research scientist at GlaxoSmithKline (GSK), where he focused on cardiovascular disease research. He moved from GSK into the biotech sector, where he joined a team that founded Pharmagene Laboratories: a company that focused on drug discovery through the application of human-tissue-based approaches. At Pharmagene he transitioned to a commercial role, taking responsibility for business development activities in the UK, US and Japan. Following his time at Pharmagene Jason held a number of commercial positions within small and medium-sized biotech companies and prior to joining Ubiquigent headed strategic alliances for the European Bioinformatics Institute, an outstation of the European Molecular Biology Laboratory (EMBL). Jason gained his BSc from the University of Hertfordshire whilst at GSK and his MBA from Imperial College London.